SOURCE: Barrier Therapeutics, Inc.

March 03, 2006 16:01 ET

Barrier Therapeutics to Present Data on Vusion™ and Sebazole™ at the American Academy of Dermatology 64th Annual Meeting

PRINCETON, NJ -- (MARKET WIRE) -- March 3, 2006 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that it will be displaying several key scientific poster presentations at the American Academy of Dermatology (AAD) 64th Annual Meeting being held in San Francisco March 3-7, 2006.

"This year at the AAD, we are happy to present additional data from 2 of our lead products, Vusion™, which was recently approved by the FDA, and Sebazole™, which is under FDA review. The progress with these products is very important as we continue to move forward in the transition of our company to a commercial organization in 2006," commented Geert Cauwenbergh, Ph.D., Chairman and CEO of Barrier Therapeutics.

Members of Barrier's commercial and development teams will be in attendance discussing the results outlined in the poster presentations during this year's annual AAD meeting. To view these posters in their entirety, please visit the Press Release section of Barrier Therapeutics' website at http://www.barriertherapeutics.com. The poster presentations are titled:

--  C Albicans is Associated with Moderate and Severe Diaper Dermatitis
    (DD); Poster Number: P2526
    
--  Clinical Trials with Miconazole Nitrate p.25% in the Treatment of
    Diaper Dermatitis Complicated by Candidiasis; Poster Number: P1926
    
--  The Treatment of Diaper Dermatitis Complicated by Candidiasis:
    Results of a Clinical Trial Involving Combination Miconazole Nitrate/Zinc
    Oxide/Petrolatum Ointment; Poster Number: P2533
    
--  Phase III Clinical Trials Confirm Safety Profile of Low-Dose Topical
    Miconazole Nitrate Ointment; Poster Number:  P2516
    
--  A 52-week Open-label Study of the Safety of Ketoconazole USP 2%
    Topical Gel in the Treament of Seborrheic Dermatitis; Poster Number: P1900
    
--  An Open-label Study to Evaluate the Systemic Absorption of
    Ketoconazole in Subjects Applying Ketoconazone USP 2% Topical Gel for the
    Treatment of Seborrheic Dermatitis; Poster Number: P1901
    
--  Oral Rambazole™ (R115866) in Patients with Moderate to Severe
    Plaque Type Psoriasis:  Safety Evaluation from a Phase IIa Trial; Poster
    Number:  P2828
    

Barrier's Booth (#2533) will be located in Hall D of the Moscone Center.

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. In addition to Vusion™ (0.25% miconazole nitrate, 15% zinc oxide and 81.35% white petrolatum) Ointment for the treatment of diaper dermatitis complicated by candidiasis, the Company currently markets Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution in the U.S. and Canada for the treatment of solar lentigines, a common condition also known as "age spots," and markets VANIQA® (eflornithine hydrochloride) Cream 13.9% in Canada for the slowing of growth of unwanted facial hair in women. Barrier's Sebazole™ (2% ketoconazole) product candidate, for the treatment of seborrheic dermatitis, is under FDA review. Barrier has other product candidates in various stages of clinical development for the treatment of onychomycosis, lamellar ichthyosis, acne, psoriasis and fungal infections. The Company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. Web site: http://www.barriertherapeutics.com.

Contact Information

  • Contacts:
    Barrier Therapeutics, Inc.
    Anne M. VanLent
    609-945-1202

    Noonan Russo
    Jane Petrino
    212-845-4274